Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 3/20 | 0.44 |
| ▸ | RXRB | P28702 | 3/20 | 0.44 |
| ▸ | RXRG | P48443 | 3/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12772068 | 0.86 | MRGPRX4 (0.52) | SGMS2MRGPRX4RXRARXRBRXRG | |
| SCHEMBL3150218 | 0.83 | SGMS2 (0.66) | SGMS2MRGPRX4RXRARXRBRXRG | |
| SCHEMBL769653 | 0.81 | XDH (0.57) | MRGPRX4XDHMAOB | |
| SCHEMBL769740 | 0.80 | MRGPRX4 (0.50) | SGMS2MRGPRX4RXRARXRBRXRG | |
| SCHEMBL769235 | 0.80 | MRGPRX4 (0.50) | SGMS2MRGPRX4RXRARXRBRXRG | |
| SCHEMBL19483249 | 0.79 | MRGPRX4 (0.55) | MRGPRX4RXRARXRBRXRGNR4A1 | |
| SCHEMBL784604 | 0.78 | MRGPRX4 (0.46) | SGMS2MRGPRX4RXRARXRBRXRG | |
| SCHEMBL17106561 | 0.78 | NPC1 (0.49) | SGMS2HTR2CSLC6A4HTR2BMAPT | |
| SCHEMBL12295554 | 0.78 | MRGPRX4 (0.68) | MRGPRX4RXRARXRBRXRGMAPT | |
| SCHEMBL799638 | 0.78 | MAPT (0.43) | MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3330255-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2408749-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2821400-B1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9751839-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751839-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751839-B2 | Process for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-06 | — | — | US | disclosed |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| CN-102361856-A | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMA | 2012-02-22 | — | — | CN | disclosed |
| CN-102361855-A | Process for the preparation of modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMA | 2012-02-22 | — | — | CN | disclosed |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327456-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | SGMS2 1264/4885MRGPRX4 554/4885RXRA 1335/4885 |
| US-20130072522-A1 | Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SLC26A4, TMEM109 | SGMS2 1264/4885MRGPRX4 554/4885RXRA 1335/4885 |
| US-20100267768-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | SGMS2 1264/4885MRGPRX4 554/4885RXRA 1335/4885 |
| US-20170096396-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | SGMS2 1264/4885MRGPRX4 554/4885RXRA 1335/4885 |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | SGMS2 1264/4885MRGPRX4 554/4885RXRA 1335/4885 |
| US-20120071504-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, CLCN2 | SGMS2 287/4885MRGPRX4 299/4885RXRA 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.